Status:

RECRUITING

Pulmonary Hypertension Association Registry

Lead Sponsor:

Pulmonary Hypertension Association, Inc.

Conditions:

Pulmonary Arterial Hypertension

Chronic Thromboembolic Pulmonary Hypertension

Eligibility:

All Genders

Brief Summary

The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people...

Eligibility Criteria

Inclusion

  • All age groups
  • Written informed consent
  • Pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH), or pediatric PH due to developmental lung disease
  • Within 6 months of first outpatient visit at a PH Care Center

Exclusion

  • Diagnosis of WSPH Group 2 pulmonary hypertension
  • Diagnosis of WSPH Group 3 pulmonary hypertension, except PH due to developmental lung disease
  • Diagnosis of WSPH Group 5 pulmonary hypertension

Key Trial Info

Start Date :

October 1 2015

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 1 2025

Estimated Enrollment :

3000 Patients enrolled

Trial Details

Trial ID

NCT04071327

Start Date

October 1 2015

End Date

December 1 2025

Last Update

November 14 2025

Active Locations (52)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 13 (52 locations)

1

Arizona Pulmonary Specialists, Ltd.

Phoenix, Arizona, United States, 85012

2

UC Davis Health

Sacramento, California, United States, 95816

3

UCSF Medical Center

San Francisco, California, United States, 94143

4

UCSF Benioff Children's Hospital

San Francisco, California, United States, 94158